Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 15 - Caught on Camera

Prediabetes remission possible without dropping pounds, our new study finds

There’s a long-held belief in diabetes prevention that weight loss is the main way to lower disease risk. Our new study challenges this.

The Conversation

US refuses to back UN declaration on noncommunicable diseases

General assembly backs new targets on cancer, diabetes and heart disease but Robert F Kennedy Jr objects

The Guardian - UK

Zika virus may raise long-term risks of type 2 diabetes – new study

It has been ten years since Brazil faced a major outbreak of the Zika virus. The alert was given in 2015, when the country’s north-eastern states reported a sudden increase in the number of babies born with unusually small heads – a condition called microcephaly.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

‘Exciting’ clinical results offer hope for new class of MS therapies

Cambridge trial suggests diabetes drug with antihistamine can partially repair damage in the nervous system

The Guardian - UK

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly’s obesity pipeline among growing investor expectations.

Benzinga

Not all diabetes is about sugar – understanding diabetes insipidus

Diabetes mellitus – known to many as type 1 and type 2 diabetes – gets all the attention with its rising global prevalence and connection to lifestyle and autoimmunity. Meanwhile, its lesser-known relative – diabetes insipidus – more quietly affects hundreds of thousands of people worldwide, but is an altogether…

The Conversation

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Gestational diabetes linked to autism and ADHD in new study

A major new analysis is drawing fresh attention to the possible links between gestational diabetes and long-term brain health in both mothers and their children. The review, which combined data from 48 studies conducted over nearly 50 years, suggests that diabetes during pregnancy may have effects that extend well beyond…

The Conversation

Scientists surprised to find human body makes its own Ozempic version

Study finds body’s ‘built-in backup plan’ for diabetes-controlling hormone production

The Independent UK

Doctors Sound Alarm Over Concerning Cause Behind Rise In Giant Baby Births

"Whose baby is this? He came out of me?"

Bored Panda

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

Daily arthritis pill could slow progression of diabetes, trial finds

The drug is already used to treat several autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and alopecia

The Independent UK

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Benzinga

New AI tool predicts risk of more than 1,000 medical conditions a decade in advance

The model can accurately predict conditions such as diabetes and cancer, and is less reliable for issues such as infectious diseases and mental health disorders.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

New type of jab helps to maintain weight loss

Experts have developed a new drug which helps tackle the underlying causes of obesity.

Benzinga

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes.

The Conversation

Serious mental illness often brings rapid weight gain – but support is missing

Being diagnosed with a serious mental illness like schizophrenia or bipolar disorder often brings an overlooked challenge: rapid and sustained weight gain. This side-effect can raise the risk of diabetes, heart disease and early death – widening an already stark life expectancy gap.

The Conversation

We studied over 160,000 pregnancies to show how your postcode affects you and your baby

Where a woman lives can shape her health during pregnancy as much as her own medical history, our new study suggests.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Study recommends ‘planetary diet’ to cut diabetes risk and emissions

Researchers say dietary changes are crucial part of effort to tackle global heating

Euronews

Combining vaping and smoking may raise risk of diabetes and prediabetes, study finds

Users of e-cigarettes have a 7 per cent higher risk of developing prediabetes compared with non-smokers, according to a new US study.

The Conversation

Weight loss drug semaglutide shown to be safe and potentialy more effective at higher dose – new findings

A higher dose of the weight loss drug semaglutide (better known by its brand name Wegovy) may help people lose up to 25% of their body weight – without the risk of severe side-effects. These findings are based on the results of two recently published clinical trials.

Benzinga

Here's Novo Nordisk's First Oral Obesity Drug In Europe With Proven Heart Health Impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

Euronews

Weight loss drugs like Ozempic work well for kids and teens, study finds. But should kids take them?

The Independent UK

Obese children as young as six could benefit from weight-loss jabs

About a third of children leaving primary school are overweight or living with obesity in England

International Business Times UK

'F* You': 10 Photos of Kathy Bates and Her Shocking Clapback to Critics After 100-Pound Weight Loss

Kathy Bates, the 77-year-old Oscar-winning actress, lost 100 pounds over several years, addressing critics who credited Ozempic alone. Motivated by a diabetes diagnosis and family health history, she transformed her lifestyle, gaining confidence, energy and renewed focus on her career.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Science Photo Library

the Medical Research Future Fund

26 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.